Survival benefit of metastasectomy plus chemotherapy versus chemotherapy alone for Krukenberg tumors from advanced stomach cancer.

4049 Background: Although systemic chemotherapy is the optimal treatment strategy for metastatic stomach cancer, several local treatments have been investigated to improve overall survival (OS) in patients with oligometastasis or limited metastasis. Because the survival benefit of metastasectomy has not been clearly validated for krukenberg tumors, we evaluated the survival benefit of ovarian metastasectomy in krukenberg tumor from stomach cancer and identified prognostic factors for survival. Methods: Of 27,103 patients who were diagnosed with stomach cancer between March 2004 and February 2013 at Yonsei University Medical Center, 244 female patients with krukenberg tumor detected by abdominal-pelvis computed tomography or gynecologic ultrasonography were included in the study and reviewed retrospectively Patients were divided into two arms according to treatment modality: arm A, metastasectomy plus chemotherapy and arm B, chemotherapy alone. Results: OS was increased by 9 and 11 months in arm A compared...